Tracking lymphoma treatment response using blood tests and PET scans
Treatments studied
Part of Cancer clinical trials.
This study follows patients with aggressive B-cell lymphoma during treatment using advanced blood tests (ctDNA) and PET imaging to detect how well the cancer is responding. The goal is to find better ways to monitor treatment in real time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have aggressive B-cell lymphoma (such as DLBCL, high-grade B-cell lymphoma, mediastinal lymphoma, or transformed follicular lymphoma)
- You have measurable tumors visible on PET scan before treatment starts
- You have never received chemotherapy or other cancer treatment for this lymphoma before
- You can have blood drawn for tumor DNA testing and a PET scan within 2 months of enrolling
- You are 18 years or older and able to speak and understand French
- You are not pregnant, planning to become pregnant, or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study uses special lab testing (“omics”) on people with certain fast-growing B-cell lymphomas to find results that can help with diagnosis and predicting outcomes. It may help by improving how clinicians identify the lymphoma type and forecast how it may behave.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This Phase 2 study tests a treatment approach guided by PET scans, plus non-invasive monitoring, for adults with limited-stage diffuse large B-cell lymphoma (a type of lymphoma). It may help by tailoring therapy based on scan and other follow-up information, aiming for better outcomes with fewer invasive steps.
Hear when a new Aggressive B-cell Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.